Abstract Number: 2409 • 2013 ACR/ARHP Annual Meeting
Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased frequency of periodontal disease (PD) and antibodies to P. gingivalis (Pg), a major periodontal pathogen. Both…Abstract Number: 2410 • 2013 ACR/ARHP Annual Meeting
Effects Of Leptin and Adiponectin On Proliferation and Activation Were Are Significantly Increased In CD4+ T Cells From Rheumatoid Arthritis Patients
Background/Purpose: In vitro and in vivo studies suggest that leptin and adiponectin are involved in the development of inflammation in RA patients. Previous findings by…Abstract Number: 2371 • 2013 ACR/ARHP Annual Meeting
Is a Single Variable, The Swollen Joint Count, Valid As An Outcome Measure Separate From Being In An Index Measure? An Analysis From The Prospective, Biologic Treatment Registry Across Canada
Background/Purpose: The importance of joint counts as measures of synovitis is reflected in their prominence in all major clinical composite indices, the Disease Activity Score…Abstract Number: 2372 • 2013 ACR/ARHP Annual Meeting
Comparison Of Proposed Biosimilar PF-05280586 With Rituximab: Nonclinical and Phase I Clinical Assessments
Background/Purpose: PF-05280586 is being developed as a potential biosimilar to rituximab, a monoclonal antibody (mAb) approved for the treatment of moderate-to-severe rheumatoid arthritis and lymphomas.…Abstract Number: 2373 • 2013 ACR/ARHP Annual Meeting
UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis
Background/Purpose: NICE guidelines recommend that patients with severe active rheumatoid arthritis (RA) be treated with a biologic disease‑modifying anti‑rheumatic drug as monotherapy (bDMARD mono) if…Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Background/Purpose: Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…Abstract Number: 2376 • 2013 ACR/ARHP Annual Meeting
A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) who are refractory to tumor necrosis factor (TNF)-inhibitors, it is still not clear which determinants are associated with…Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…Abstract Number: 2378 • 2013 ACR/ARHP Annual Meeting
Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Mavrilimumab (CAM-3001)…Abstract Number: 2379 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients With Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation Of Etanercept Is Superior Both Clinically and Radiographically To Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
Background/Purpose: The randomized clinical trial “DOSERA” has shown that in patients receiving concomitant methotrexate (MTX) therapy, continuation of etanercept (ETN) at 50 mg wkly is…Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…Abstract Number: 2381 • 2013 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
Background/Purpose: GLPG0634 is an oral, selective inhibitor of Janus kinase 1 (JAK1). JAKs signal for cytokines and growth factors, including those involved in rheumatoid arthritis…Abstract Number: 2382 • 2013 ACR/ARHP Annual Meeting
B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Background/Purpose: Rituximab is a safe and effective treatment in rheumatoid arthritis (RA), however the current treatment regimen requires to wait for a clinical relapse before…Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
ACR Meeting Abstracts